Latest Investigation News

Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.

Investigator Silver has locked in a robust Definitive Feasibility Study for its Paris Silver Project, backed by a strategic A$55 million placement to fast-track early works and financing.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

Aurelia Metals has successfully extended high-grade mineralisation at its Federation Mine by approximately 70 metres and discovered a new polymetallic lens, the Harley Lens, signalling further growth potential in the Nymagee District.

Prospect Resources has significantly boosted its Mumbezhi Copper Project resource base by 63%, lifted contained copper by 50%, and secured A$45 million in fresh capital to fund an aggressive drilling campaign starting May 2026.

Sandfire Resources faced a tragic fatality at its Magdalena mine and production challenges in Q3 FY26, yet sustained financial strength and advanced its Kalkaroo project, keeping full-year copper equivalent guidance intact.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Hillgrove Resources posted a record 3,120 tonnes of copper production in Q1 2026, driving a 22% jump in cash to $25.2 million. The company’s exploration at Emily Star and Nugent underpins ambitions to surpass 2 million tonnes annual throughput.

Enova Mining has initiated a deep diamond drilling campaign at its Charley Creek Rare Earth Project in the Northern Territory, aiming to unlock the potential of deeper bedrock rare earth mineralisation following encouraging earlier air-core results.

South32's March quarter saw a tragic fatality at Worsley Alumina and weather disruptions, yet the miner delivered solid operational results and progressed its Hermosa zinc-lead-silver project. Production guidance was mostly maintained, with a notable revision lower for Australia Manganese due to water management issues.

Starpharma has secured FDA alignment on the clinical development plan for its DEP® HER2 radiotherapy candidate, paving the way for a first-in-human phase 1 study in advanced HER2-positive cancers scheduled for H2 2026.

MA Financial Group reported a 44% year-on-year jump in assets under management to $14.8 billion in 1Q26, underpinned by strong lending growth and transactional activity despite asset sales and market volatility.